List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 19 studies with search of: "PharmaMar" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed A Study of Aplidin (Plitidepsin) in Subjects With Relapsing or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Plitidepsin
2 Recruiting A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Condition: Solid Tumors
Intervention: Drug: PM02734
3 Terminated Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Condition: Relapsed/Refractory Leukemia
Intervention: Drug: Plitidepsin plus Cytarabine
4 Recruiting Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Condition: Advanced Malignant Solid Tumors
Interventions: Drug: PM02734 and erlotinib;   Drug: Erlotinib
5 Recruiting Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: PM01183
6 Terminated A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Aplidin (plitidepsin)
7 Recruiting Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Drug: Aplidin®
8 Terminated A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
Conditions: Solid Tumors;   Lymphoma
Intervention: Drug: Zalypsis (PM00104)
9 Recruiting Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Advanced Solid Tumors;   Lymphomas
Interventions: Drug: Plitidepsin and Sorafenib;   Drug: Gemcitabine and Plitidepsin
10 Active, not recruiting A Study Comparing the Combination of Doxil and Yondelis, to Doxil Alone for Subjects With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Yondelis;   Drug: DOXIL;   Drug: DOXIL
11 Completed A Safety Study Utilizing Yondelis and Doxorubicin in Patients With Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: Yondelis and doxorubicin
12 Completed ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: ET 743
13 Completed Phase 2 Study of ET-743 in Subjects With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: ET-743
14 Not yet recruiting A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-Based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)
Conditions: Translocation-Related Sarcomas (TRS);   Soft Tissue Sarcomas
Intervention: Drug: Trabectedin, ET 743 and Yondelis
15 Completed ET-743 in Subjects With Advanced Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: ET-743
16 Recruiting A Placebo-Controlled Study Evaluating the Potential Effects of Trabectedin on the Heart in Patients With Advanced Cancer
Condition: Neoplasm Metastases
Intervention: Drug: Trabectedin, YONDELIS®
17 Completed Phase 2 Study of ET-743 in Persistent or Recurrent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: ET-743
18 Active, not recruiting A Study of ET743 in Subjects With Advanced Liposarcoma or Leiomyosarcoma
Conditions: Liposarcoma;   Leiomyosarcoma
Interventions: Drug: Yondelis;   Drug: Yondelis
19 Recruiting ET-743 in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: ET-743 (YONDELIS)

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services